Corporate Reorganization and Re-Focused Strategy Propels Advancement San Diego, CA – October 31, 2023 – Okogen, an ophthalmic biotechnology company, today announced the initiation of a Phase IIb clinical trial evaluating OKG-0303 for Acute Infectious Conjunctivitis (“Pink Eye”) to be conducted in
Lead candidate, OKG-0502, to address significant unmet medical need. San Diego, CA and Melbourne, AUS – March 8, 2022 – Okogen, an ophthalmic biotechnology company, today announced the appointment of Joshua Moriarty as the new Chief Executive Officer (CEO). Mr. Moriarty will
Okogen, a clinical-stage, specialty biotechnology company focused on developing ophthalmic therapeutics, today announced the initiation of a Phase 2 clinical trial (RUBY) that is designed to evaluate the safety and efficacy of OKG-0301 in the treatment of acute adenoviral conjunctivitis.
Okogen, a clinical-stage, specialty biotechnology company focused on developing ophthalmic therapeutics, today announced the initiation of a Phase 2 clinical trial (RUBY) that is designed to evaluate the safety and efficacy of OKG-0301 in the treatment of acute adenoviral conjunctivitis.
Rosanne Michie of Optometry Austrialia reviews Okogen’s upcoming Australian trial that aims to fill the absence of approved therapies to treat the underlying cause of viral conjunctivitis.
In this article from Mommybites, Francis Mah, MD discusses the causes of pink eye, common symptoms, prevention tips, steps you can take for home treatment and when to seek the help of an eye care specialist.
Okogen innovates a novel treatment for a common and often serious ophthalmic condition with no approved therapies. Hear the phrase “pink eye” and more than likely you immediately picture red, runny, painful eyes. You might even feel your own eyes
The San Diego Union Tribune covers Okogen’s receival of $10 million in Series A funding to further invest in treatments for viral conjunctivitis.
Okogen, Inc., a developer of ophthalmic anti-infective drugs, announced $10 million in Series A funding from Brandon Capital’s Medical Research Commercialisation Fund (MRCF) to advance the ongoing development of the company’s lead candidate for viral conjunctivitis (commonly known as pink eye), OKG-0301.
Okogen, Inc., a developer of ophthalmic anti-infectives, received a notice of allowance from the United States Patent and Trademark Office for the use of ranpirnase for the treatment of viral conjunctivitis. “The claims granted under 3IPOK1.0002US, in combination with the our existing in-licensed portfolio, further reinforce our strong intellectual property position,” said Brian M. Strem, Ph.D., Chief Executive Officer of Okogen.
© 2023 Okogen, Inc. All Rights Reserved
United States
Okogen, Inc.
332 Encinitas Blvd. Suite 102
Encinitas, CA 92024, USA
Australia
Okogen Pty Ltd
Level 9, 31 Queen St
Melbourne, VIC 3000 AUS
